Short form 36 assessed health-related quality of life after focal spasticity therapy

Journal of Rehabilitation Medicine

Volumn 41, Issue 4, 2009, Pages 279-281

  Bergfeldt, Ulla ^a   Sköld, Camilla ^a   Julin, Per ^a  

^a DANDERYD HOSPITAL   (Sweden)

Author keywords

Botulinum toxin type A; Health related quality of life; Physical therapy; Short form 36; Spasticity

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

ADULT; AGED; ARTICLE; CEREBRAL PALSY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HUMAN; INTERVENTION STUDY; MALE; MOTOR NEURON DISEASE; MOTOR PERFORMANCE; MUSCLE WEAKNESS; OBSERVATIONAL STUDY; ORTHOPEDIC SHOE; ORTHOSIS; PHYSIOTHERAPY; PROSPECTIVE STUDY; QUALITY OF LIFE; SHORT FORM 36; SPASTICITY; STROKE; DAILY LIFE ACTIVITY; INTRAMUSCULAR DRUG ADMINISTRATION; MIDDLE AGED; QUESTIONNAIRE; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; BOTULINUM TOXIN TYPE A; CEREBRAL PALSY; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; MOTOR NEURON DISEASE; MUSCLE SPASTICITY; NEUROMUSCULAR AGENTS; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; STROKE; TREATMENT OUTCOME;

EID: 61749104220     PISSN: 16501977     EISSN: None     Source Type: Journal    
DOI: 10.2340/16501977-0318     Document Type: Article

References (11)

1. Finch E, Brooks D, Stratford PW, Mayo NE, editors. Physical rehabilitation outcome measures; a guide to enhanced clinical decision making, 2nd edition. Ontario: Lippincott Williams & Wilkins; 2002, p. 270-272.
2. Porter S, editor. Dictionary of physiotherapy. Edinburgh: Butterworth Heinemann; 2005, p. 149.
3. Turner-Stokes L, Ward A, editors. Guidelines for the use of botulinum toxin (BTX) in the management of spasticity in adults. London: Royal College of Physicians; 2002.
4. Richardson D, Thompson AJ. Botulinum toxin: its use in the treatment of acquired spasticity in adults. Physiotherapy 1999; 85: 541-551.
5. Bergfeldt U, Borg K, Kullander K, Julin P. Focal spasticity therapy with botulinum toxin: effects on functions, ADL, and pain in 100 adult patients. J Rehabil Med 2006; 38: 166-171.
6. Sullivan M, Karlsson J, Taft C, editors. SF-36 Hälsoenkät: Svensk Manual och Tolkningsguide, 2:a upplagan. [Swedish manual and interpretation guide, 2nd edition]. Gothenburg: Sahlgrenska University Hospital; 2002 (in Swedish).
7. Mayer NH, Simpson DM. Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult-onset muscle overactivity in patients with an upper motoneuron lesion. In: Mayer NH, Simpson DM, editors. Spasticity: etiology, evaluation, management and the role of botulinum toxin. New York: We Move; 2002, p. 154-165.
8. McHorney CA, Ware JE Jr, Lu JFR, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994; 32: 40-66.
9. World Health Organization (WHO). International classification of functioning, disability and health (ICF). Geneva: WHO; 2001.
10. Childers MK, Brashear A, Jozefczyk P, Reding M, Alexander D, Good D, et al. Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity after a stroke. Arch Phys Med Rehabil 2004; 85: 1063-1069.
11. Finch E, Brooks D, Stratford PW, Mayo NE, editors. Physical rehabilitation outcome measures; a guide to enhanced clinical decision making, 2nd edition. Ontario: Lippincott Williams & Wilkins; 2002, p. 15-25.